Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta and multiple sclerosis: look at the evidence.

F Patti1, A Reggio

  • 1Centro Sclerosis Multipla, Dipartmento di Neuroscienze, Università di Catania, Italy.

International Journal of Clinical Practice. Supplement
|February 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.

Journal of neurology·2025
Same author

Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.

Journal of neurology·2024
Same author

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Journal of medical economics·2023
Same author

Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors.

Multiple sclerosis and related disorders·2023
Same author

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2022
Same author

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

BMC medical research methodology·2022

Interferon beta-1a offers significant advantages over glatiramer acetate for relapsing-remitting multiple sclerosis (RRMS). Early treatment with subcutaneous interferon beta-1a (44 mcg three times weekly) is most effective for RRMS management.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) management relies on disease-modifying therapies like glatiramer acetate (GA) and interferon beta (IFN beta).
  • Direct comparative efficacy studies between GA and IFN beta in MS are limited.
  • Optimal IFN beta therapy regimens for MS patients remain a subject of debate.

Purpose of the Study:

  • To review clinical trials comparing different interferon beta-1a (IFN beta-1a) treatment regimens.
  • To evaluate the efficacy of IFN beta-1a compared to glatiramer acetate (GA) in relapsing-remitting MS (RRMS).
  • To determine the optimal treatment strategy for RRMS using IFN beta-1a.

Main Methods:

  • Focus on clinical trials of interferon beta-1a (IFN beta-1a).

Related Experiment Videos

  • Analysis of studies allowing direct comparison of different IFN beta-1a treatment regimens.
  • Review of data comparing IFN beta-1a with glatiramer acetate (GA).

    • Main Results:

    • Interferon beta (IFN beta), specifically IFN beta-1a, demonstrates superior efficacy compared to glatiramer acetate (GA) in treating relapsing-remitting MS (RRMS).
    • High-dose subcutaneous IFN beta-1a (44 mcg three times weekly) is significantly more effective than lower-dose intramuscular IFN beta-1a (30 mcg once weekly).

    Conclusions:

    • Interferon beta-1a offers significant advantages over glatiramer acetate for RRMS treatment.
    • The optimal regimen for RRMS is subcutaneous IFN beta-1a (44 mcg t.i.w.).
    • Early initiation of IFN beta-1a treatment post-diagnosis is crucial for optimal RRMS management.